Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
CHICAGO — Typically, when you update your early-stage data with a couple of new complete responses to report, the biopharma world finds other things to focus on. But if you’re Incyte, with a $27 billion market cap $INCY centered on its lead IDO1 therapy epacadostat, the biopharma world will make an exception for you.
So it was on Saturday at ASCO, when Incyte adjusted the abacus on its non-small cell small combo lung cancer study for epacadostat and Keytruda, moving 2 of 14 responses reported recently in its ASCO abstract out of the partial side to the complete responses lineup.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
